ASINEX is interested in research, development and commercialization relationships with pharmaceutical and biotechnology companies.
ASINEX has mastered its Compound-to-Target™ platform that facilitates translation of innovative small molecule and macrocyclic chemistry into pre-clinical leads focusing on specific oncogenic pathways:
・ Apoptotic pathway
・ Cyclin-dependent kinase pathways
・ Wnt/β-catenin signaling pathway
In addition to oncology, the platform provides valuable starting points for antibacterial R&D.
For more information, please contact us.